Treatment with antiangiogenic drugs
Saijo, N.
Nihon Rinsho. Japanese Journal of Clinical Medicine 68(6): 1007-1013
2010
ISSN/ISBN: 0047-1852 PMID: 20535948 Document Number: 642675
Antiangiogenesis therapy with bevacizumab demonstrated better response rate, progression free survival and overall survival in various kind of tumors including colon, breast, lung and renal cancer. It mainly potentiates antitumor activity of cytotoxic drugs. Problems remain in high cost of antibody and adverse events such as hypertension and bleeding. Small molecules of VEGF-TKI could not show survival benefit by many randomized controlled trials except for renal and hepatic cancer.